Anixa Biosciences, Inc. (ANIX)
Nasdaq · Healthcare · Biotechnology
$2.950.00%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $103M
- 52-week range
- $2.32 – $5.46
- 52-week change
- −28.22%
- EPS (trailing)
- −$0.32
- Analyst rating
- 1.3 Strong buy
Fiscal year to Oct 2025
- Net income
- −$10.9M
- Diluted EPS
- −$0.34
From the company’s annual report on SEC EDGAR.
About Anixa Biosciences, Inc.
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged in the development of a vaccine against breast cancer; and the development of a vaccine discovery program to develop additional cancer vaccines to address intractable cancers, including high incidence malignancies in lung, colon, and prostate. Its vaccine technologies focus on the discovery of additional retired proteins that may be associated with other forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
Headquarters: San Jose, United States · 4 employees · anixa.com